托法替尼治疗成人和青少年重度斑秃

Q2 Medicine

Journal of Investigative Dermatology Symposium Proceedings Pub Date : 2018-01-01 DOI:10.1016/j.jisp.2017.10.003

Lucy Yichu Liu , Brett Andrew King

{"title":"托法替尼治疗成人和青少年重度斑秃","authors":"Lucy Yichu Liu , Brett Andrew King","doi":"10.1016/j.jisp.2017.10.003","DOIUrl":null,"url":null,"abstract":"<div><p>Alopecia areata (AA) is an autoimmune disease affecting people of all ages. There is currently no cure for AA, and a highly efficacious therapy for severe AA has been elusive. Recently, scientific advances have identified the Janus kinase pathway as a target for treatment. Both Janus kinase inhibitors approved by the US Food and Drug Administration, tofacitinib and ruxolitinib, have shown promise in open-label clinical trials. This review summarizes the results of long-term use of tofacitinib in severe AA.</p></div>","PeriodicalId":54791,"journal":{"name":"Journal of Investigative Dermatology Symposium Proceedings","volume":"19 1","pages":"Pages S18-S20"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.003","citationCount":"27","resultStr":"{\"title\":\"Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents\",\"authors\":\"Lucy Yichu Liu , Brett Andrew King\",\"doi\":\"10.1016/j.jisp.2017.10.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Alopecia areata (AA) is an autoimmune disease affecting people of all ages. There is currently no cure for AA, and a highly efficacious therapy for severe AA has been elusive. Recently, scientific advances have identified the Janus kinase pathway as a target for treatment. Both Janus kinase inhibitors approved by the US Food and Drug Administration, tofacitinib and ruxolitinib, have shown promise in open-label clinical trials. This review summarizes the results of long-term use of tofacitinib in severe AA.</p></div>\",\"PeriodicalId\":54791,\"journal\":{\"name\":\"Journal of Investigative Dermatology Symposium Proceedings\",\"volume\":\"19 1\",\"pages\":\"Pages S18-S20\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.jisp.2017.10.003\",\"citationCount\":\"27\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Investigative Dermatology Symposium Proceedings\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1087002417300357\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Dermatology Symposium Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1087002417300357","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 27

摘要

斑秃(AA)是一种影响所有年龄人群的自身免疫性疾病。目前还没有治愈AA的方法，对严重AA的高效治疗也一直难以捉摸。最近，科学进展已经确定了Janus激酶途径作为治疗的靶点。美国食品和药物管理局批准的两种Janus激酶抑制剂tofacitinib和ruxolitinib在开放标签临床试验中显示出希望。本文综述了长期使用托法替尼治疗重度AA的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents

Alopecia areata (AA) is an autoimmune disease affecting people of all ages. There is currently no cure for AA, and a highly efficacious therapy for severe AA has been elusive. Recently, scientific advances have identified the Janus kinase pathway as a target for treatment. Both Janus kinase inhibitors approved by the US Food and Drug Administration, tofacitinib and ruxolitinib, have shown promise in open-label clinical trials. This review summarizes the results of long-term use of tofacitinib in severe AA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Investigative Dermatology Symposium Proceedings 医学-皮肤病学

自引率

0.00%

发文量

期刊介绍： Journal of Investigative Dermatology Symposium Proceedings (JIDSP) publishes peer-reviewed, invited papers relevant to all aspects of cutaneous biology and skin disease. Papers in the JIDSP are often initially presented at a scientific meeting. Potential topics include biochemistry, biophysics, carcinogenesis, cellular growth and regulation, clinical research, development, epidemiology and other population-based research, extracellular matrix, genetics, immunology, melanocyte biology, microbiology, molecular and cell biology, pathology, pharmacology and percutaneous absorption, photobiology, physiology, and skin structure.